Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Stock Information for Aptevo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.